IDYA [NASD]
IDEAYA Biosciences, Inc.
Index- P/E- EPS (ttm)-1.48 Insider Own6.55% Shs Outstand38.59M Perf Week10.79%
Market Cap387.22M Forward P/E- EPS next Y-2.38 Insider Trans0.00% Shs Float36.12M Perf Month-2.35%
Income-54.80M PEG- EPS next Q-0.46 Inst Own94.10% Short Float10.46% Perf Quarter-28.83%
Sales32.10M P/S12.06 EPS this Y-1.20% Inst Trans5.64% Short Ratio9.72 Perf Half Y-56.65%
Book/sh7.48 P/B1.39 EPS next Y-18.70% ROA-14.90% Target Price27.75 Perf Year-46.77%
Cash/sh6.76 P/C1.53 EPS next 5Y- ROE-19.10% 52W Range8.14 - 28.00 Perf YTD-56.13%
Dividend- P/FCF- EPS past 5Y- ROI-16.70% 52W High-62.96% Beta-
Dividend %- Quick Ratio4.50 Sales past 5Y- Gross Margin- 52W Low27.40% ATR0.86
Employees87 Current Ratio4.50 Sales Q/Q58.30% Oper. Margin- RSI (14)50.23 Volatility9.16% 9.16%
OptionableYes Debt/Eq0.00 EPS Q/Q-27.80% Profit Margin- Rel Volume0.71 Prev Close11.43
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume388.62K Price10.37
Recom1.60 SMA204.32% SMA50-5.57% SMA200-44.95% Volume275,380 Change-9.27%
Mar-10-22Upgrade Stifel Hold → Buy $27 → $20
Sep-23-21Initiated Stifel Hold $27
Jun-04-21Resumed Robert W. Baird Outperform $28
Mar-11-21Initiated Guggenheim Buy $32
Oct-07-20Initiated Wedbush Outperform $21
Sep-01-20Initiated Northland Capital Outperform $28
Jul-13-20Upgrade JP Morgan Neutral → Overweight $28
Jun-17-20Reiterated H.C. Wainwright Buy $13 → $22
Apr-06-20Initiated H.C. Wainwright Buy $13
Mar-13-20Initiated ROTH Capital Buy $12
Oct-17-19Initiated Oppenheimer Outperform $17
Sep-10-19Initiated Robert W. Baird Outperform
Jun-17-19Initiated JP Morgan Neutral $15
Jun-17-19Initiated Jefferies Buy $14
Jun-17-19Initiated Citigroup Buy $20
May-10-22 07:15AM  
06:00AM  
May-06-22 09:59AM  
May-03-22 06:00AM  
May-02-22 06:00AM  
Apr-27-22 05:25PM  
Apr-06-22 06:00AM  
Mar-17-22 01:54PM  
Mar-15-22 08:48AM  
07:15AM  
06:00AM  
05:55AM  
Mar-14-22 06:00AM  
Mar-10-22 05:55PM  
Mar-08-22 06:00AM  
Mar-01-22 05:55PM  
06:00AM  
Feb-24-22 08:35AM  
Feb-15-22 08:22AM  
Feb-14-22 09:49AM  
Feb-01-22 06:00AM  
Jan-31-22 06:51AM  
06:00AM  
Jan-10-22 06:00AM  
Jan-05-22 06:00AM  
Jan-04-22 06:00AM  
Jan-03-22 06:00AM  
Dec-21-21 01:38AM  
Dec-07-21 07:00AM  
Nov-30-21 06:00AM  
Nov-29-21 06:00AM  
Nov-15-21 08:44AM  
06:01AM  
Nov-04-21 03:01PM  
Nov-01-21 06:00AM  
Oct-18-21 06:00AM  
Sep-10-21 04:57PM  
Aug-30-21 06:00AM  
Aug-16-21 08:26AM  
Aug-10-21 07:15AM  
06:00AM  
Aug-02-21 06:00AM  
Jul-12-21 04:11PM  
Jul-08-21 06:39AM  
Jul-07-21 09:29PM  
08:01AM  
Jul-06-21 04:01PM  
Jun-28-21 06:00AM  
May-24-21 06:01AM  
May-16-21 05:21AM  
May-10-21 07:30AM  
06:00AM  
06:00AM  
May-06-21 06:00AM  
Apr-19-21 06:00AM  
Apr-18-21 08:30AM  
Apr-16-21 06:00AM  
Apr-15-21 04:01PM  
06:00AM  
Mar-23-21 10:24AM  
07:30AM  
06:05AM  
06:05AM  
Mar-11-21 06:00AM  
Mar-01-21 06:00AM  
Feb-22-21 06:00AM  
Feb-17-21 06:00AM  
Feb-15-21 01:12AM  
Feb-08-21 06:00AM  
Feb-01-21 06:00AM  
Jan-19-21 06:00AM  
Jan-11-21 06:00AM  
Jan-05-21 06:00AM  
Jan-04-21 06:00AM  
Dec-14-20 06:00AM  
Dec-11-20 10:23PM  
Dec-08-20 12:43PM  
Nov-16-20 11:19PM  
Nov-15-20 08:50AM  
Nov-12-20 06:00AM  
Nov-02-20 06:00AM  
Oct-22-20 06:00AM  
Sep-24-20 08:15AM  
06:00AM  
Sep-04-20 12:52PM  
Sep-02-20 06:21PM  
Aug-31-20 06:00AM  
Aug-19-20 01:33PM  
Aug-12-20 07:30AM  
06:00AM  
Aug-07-20 08:33AM  
Aug-05-20 04:21PM  
Aug-04-20 06:00AM  
Jul-16-20 06:00AM  
Jul-14-20 06:00AM  
Jul-09-20 06:00AM  
Jun-30-20 06:00AM  
Jun-22-20 04:35PM  
Jun-17-20 09:34PM  
09:53AM  
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients with solid tumors having MTAP deletions; PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dillon Michael P.SVP, Chief Scientific OfficerOct 04Option Exercise11.081,50016,62080,289Oct 07 04:11 PM
Dillon Michael P.SVP, Chief Scientific OfficerOct 04Sale26.361,50039,54578,789Oct 07 04:11 PM
Dillon Michael P.SVP, Chief Scientific OfficerSep 08Option Exercise6.8711,38478,26490,173Sep 09 07:24 PM
Dillon Michael P.SVP, Chief Scientific OfficerSep 08Sale27.4211,384312,09378,789Sep 09 07:24 PM
Dillon Michael P.SVP, Chief Scientific OfficerSep 07Option Exercise4.3111650078,905Sep 09 07:24 PM
Dillon Michael P.SVP, Chief Scientific OfficerSep 07Sale27.461163,18578,789Sep 09 07:24 PM
Stone Paul A.SVP, Chief Financial OfficerSep 07Sale27.422,50068,54212,944Sep 09 05:41 PM
Dillon Michael P.SVP, Chief Scientific OfficerSep 02Sale25.0910,000250,94378,789Sep 07 06:48 PM
Dillon Michael P.SVP, Chief Scientific OfficerAug 09Option Exercise4.311,5006,465100,289Aug 11 05:19 PM
Dillon Michael P.SVP, Chief Scientific OfficerAug 09Sale22.9811,500264,26988,789Aug 11 05:19 PM
Throne JasonSVP, General CounselJul 27Option Exercise13.3410,000133,40010,000Jul 29 05:17 PM
Dillon Michael P.SVP, Chief Scientific OfficerJul 27Option Exercise5.6210,00056,150108,789Jul 29 05:18 PM
Throne JasonSVP, General CounselJul 27Sale25.1710,000251,6830Jul 29 05:17 PM
Dillon Michael P.SVP, Chief Scientific OfficerJul 27Sale25.1510,000251,46098,789Jul 29 05:18 PM
Throne JasonSVP, General CounselJul 06Option Exercise8.5210,00085,22910,000Jul 08 07:00 PM
Dillon Michael P.SVP, Chief Scientific OfficerJul 06Option Exercise6.921,50010,380100,289Jul 08 07:01 PM
Dillon Michael P.SVP, Chief Scientific OfficerJul 06Sale22.241,50033,35898,789Jul 08 07:01 PM
Throne JasonSVP, General CounselJul 06Sale22.2410,000222,4080Jul 08 07:00 PM
Dillon Michael P.SVP, Chief Scientific OfficerJun 17Option Exercise6.923,89326,940102,682Jun 17 08:59 PM
Dillon Michael P.SVP, Chief Scientific OfficerJun 17Sale22.493,89387,54098,789Jun 17 08:59 PM
Dillon Michael P.SVP, Chief Scientific OfficerJun 16Option Exercise6.921,1077,66099,896Jun 17 08:59 PM
Dillon Michael P.SVP, Chief Scientific OfficerJun 16Sale22.471,10724,87398,789Jun 17 08:59 PM
Dillon Michael P.SVP, Chief Scientific OfficerJun 07Option Exercise6.921,50010,380100,289Jun 09 06:12 PM
Dillon Michael P.SVP, Chief Scientific OfficerJun 07Sale20.221,50030,33398,789Jun 09 06:12 PM